Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Review Article

JCR. 2014; 1(1): 25-28


A REVIEW ON IRBESARTAN CO ADMINISTERED WITH ATORVASTATIN FOR THE TREATMENT OF CARDIAC RISK

PARAS VIRANI, RAJANIT SOJITRA, HASUMATI RAJ, VINEET JAIN.

Abstract
Hypertension and Hypercholesterolemia are a major public health problem in the developed Countries recently. Hypertension and hypercholesterolemia are frequently treated with antihypertensive drugs like calcium-channel blockers, angiotensin-converting enzyme inhibitors, and angiotensinII (AT1) receptor blockers, and statins. Irbesartan is angiotensin II receptor type 1 antagonist and widely used in treatment of hypertension condition. Atorvastatin is HMG CoA reductase inhibitor and widely used in treatment of hyper lipidaemias condition. .Combination of irbesartan and atorvastatin is used in the treatment of cardiovascular diseases like hypertension and hyper lipidemias. So this combination therapy gives antihypertensive and antilipidemic effects in the treatment of coronary artery diseases.

Key words: Irbesartan, Atorvastatin, Antihypertensive, Antilipidemic, Pharmacology, Combination Therapy.



Similar Articles

Promoter CAG is more efficient than hepatocyte‑targeting TBG for transgene expression via rAAV8 in liver tissues.
Kang J, Hang L, Zheng W, Luo J, Zhang X, Song Y, Liu A
Molecular medicine reports. 2022; 25(1):

Organelle-inspired supramolecular nanomedicine to precisely abolish liver tumor growth and metastasis.
Zhan J, Wang Y, Ma S, Qin Q, Wang L, Cai Y, Yang Z
Bioactive materials. 2022; 9(): 120-133

Interrater agreement of contouring of the neurovascular bundles and internal pudendal arteries in neurovascular-sparing magnetic resonance-guided radiotherapy for localized prostate cancer.
Teunissen FR, Wortel RC, Wessels FJ, Claes A, van de Pol SMG, Rasing MJA, Meijer RP, van Melick HHE, de Boer JCJ, Verkooijen HM, van der Voort van Zyp JRN
Clinical and translational radiation oncology. 2022; 32(): 29-34

Bispecific antibody characterization by a combination of intact and site-specific/chain-specific LC/MS techniques.
Duivelshof BL, Beck A, Guillarme D, D'Atri V
Talanta. 2022; 236(): 122836

Technological Advancements for Treating Erectile Dysfunction and Peyronie's Disease.
Campbell JD, Matti D, Abed H, Di Pierdominico A
The Urologic clinics of North America. 2022; 49(1): 175-184


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites